<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="of COVID-19. Immunocompromised patients are at high risk for COVID-19" exact="infection" post="and may lead to death. Scientist and government agencies"/>
 <result pre="putting forward their best efforts and resources for the effective" exact="treatment" post="of human coronavirus infections; however, neither vaccines nor antiviral"/>
 <result pre="however, neither vaccines nor antiviral drugs are available for the" exact="treatment" post="of human coronaviruses (HCoV) infections such as SARS (severe"/>
 <result pre="reports have addressed the clinical features and current status of" exact="treatment" post="for COVID-19; we have adequately addressed these topics in"/>
 <result pre="putting forward their best efforts and resources for the effective" exact="treatment" post="of human coronavirus (HCoV) infections. However, neither vaccines nor"/>
 <result pre="However, neither vaccines nor antiviral drugs are approved for the" exact="treatment" post="of HCoV infections such as SARS, MERS (Middle Eastern"/>
 <result pre="coronaviruses are highly contagious [15] and can cause severe respiratory" exact="infection" post="[16] and acute respiratory distress syndrome (ARDS), followed by"/>
 <result pre="the comprehensive clinical features of the disease. Furthermore, information about" exact="treatment" post="options for COVID-19 is not adequate. In this report,"/>
 <result pre="process of the disease, epidemiologic outcomes, pathogenetic data, clinical features," exact="diagnosis" post="tools, treatment strategies, and prevention and control pathways. 2."/>
 <result pre="the disease, epidemiologic outcomes, pathogenetic data, clinical features, diagnosis tools," exact="treatment" post="strategies, and prevention and control pathways. 2. Structure of"/>
 <result pre="were admitted to the hospitals by 2 January 2020. The" exact="diagnosis" post="of these patients confirmed COVID-19. Thailand was the first"/>
 <result pre="Previously, it was thought that children were less susceptible to" exact="infection" post="owing to a lack of evidence, but on 5"/>
 <result pre="[46]. Another parameter for understanding the severity and prognosis of" exact="infection" post="is the case fatality ratio (CFR), which is calculated"/>
 <result pre="MIP1Î±, GCSF, and TNFÎ±, which exaggerated the severity of the" exact="infection" post="[58]. This exaggerated immune response destroys the lungâ€™s infrastructure"/>
 <result pre="exaggerated immune response responsible for the enhanced severity of the" exact="infection" post="[60,62]. As discussed earlier, ACE2 is the receptor for"/>
 <result pre="was conducted to get insight into the relationship between the" exact="prevalence" post="of COVID-19 disease and the genetic differences in the"/>
 <result pre="anosmia was observed in 73% of patients prior to the" exact="diagnosis" post="of COVID-19 and was the early symptom in 26.6%"/>
 <result pre="be the representative symptom of COVID-19 [72,73]. 7. Diagnosis The" exact="diagnosis" post="and treatment program for COVID-19 was formulated by NHC"/>
 <result pre="representative symptom of COVID-19 [72,73]. 7. Diagnosis The diagnosis and" exact="treatment" post="program for COVID-19 was formulated by NHC of China"/>
 <result pre="if there is not any clear exposure history. The serology" exact="testing" post="for COVID-19 is helpful and provides the basis for"/>
 <result pre="serological antibody test can improve the sensitivity of COVID-19 case" exact="detection" post="[80]. This approach allowed to test a huge number"/>
 <result pre="rapidly in the community, minimizing the waiting time for molecular" exact="testing" post="and preventing the health-management system from being overwhelmed [79]."/>
 <result pre="CT has been recognized as a significant indicator for COVID-19" exact="diagnosis" post="in different epidemic areas [15,31,81]. It can be said"/>
 <result pre="the chest CT is an essential procedure for the timely" exact="detection" post="and management of this infection. However, it should be"/>
 <result pre="considered sensitive and specific, and this information helps fortify the" exact="diagnosis" post="of COVID-19 [83]. Laboratory findings can be helpful in"/>
 <result pre="no specific and sensitive therapeutic regimen is available for the" exact="treatment" post="of COVID-19. However, the primary step is isolation to"/>
 <result pre="for the treatment of COVID-19. However, the primary step is" exact="isolation" post="to prevent any type of contact that later may"/>
 <result pre="symptoms, it should be managed at their residence with proper" exact="counseling" post="to patients about the critical signs and symptoms. The"/>
 <result pre="[91]. Antiviral therapy is also being tried to manage the" exact="infection" post="[92]. Critical patients show an unhealthy immune response that"/>
 <result pre="discussed earlier, inflammatory cytokines are released at the site of" exact="infection" post="and cause infiltration of lungs. Clinical trials are underway"/>
 <result pre="the USA authorized the emergency use of remdesivir for the" exact="treatment" post="of COVID-19 [106]. The recent version of treatment guidelines"/>
 <result pre="for the treatment of COVID-19 [106]. The recent version of" exact="treatment" post="guidelines by NHC recommends the use of lopinavir/ritonavir and"/>
 <result pre="the use of lopinavir/ritonavir and IFN-Î±. The first version of" exact="treatment" post="guidelines was issued on 15 January 2020, later revised"/>
 <result pre="ribavirin, and IFN-Î± were added in the 5th edition of" exact="treatment" post="guidelines for combating COVID-19. Later, arbidol and chloroquine phosphate"/>
 <result pre="clinical efficacy. Potential drugs included in the 6th edition of" exact="treatment" post="guidelines by NHC of China, as shown in Table"/>
 <result pre="(400 mg/100 mg), no clinical improvement was observed by this" exact="treatment" post="beyond standard care [108]. On the basis of the"/>
 <result pre="penciclovir, ribavirin, and favipiravir require high doses to decrease the" exact="infection" post="and are supposed to be less effective [90]. Chloroquine"/>
 <result pre="listed in Table 4 to gain a better understanding of" exact="treatment" post="[116]. An open-label, non-randomized clinical trial showed that hydroxychloroquine"/>
 <result pre="An open-label, non-randomized clinical trial showed that hydroxychloroquine (600 mg/day)" exact="treatment" post="is magnificently related to a decreased rate of viral"/>
 <result pre="TMPRSS2 is the most crucial phase for the prognosis of" exact="infection" post="into the host, so the viral infection can be"/>
 <result pre="the prognosis of infection into the host, so the viral" exact="infection" post="can be controlled with the use of protease inhibitors,"/>
 <result pre="therapy of azithromycin with hydroxychloroquine showed significant activity against COVID-19" exact="infection" post="[124]. Table 5 delineates the potential therapeutics against COVID-19."/>
 <result pre="This study published recently suggests that immunity acquired following primary" exact="infection" post="with SARS-CoV-2 may protect upon subsequent exposure to the"/>
 <result pre="and Control Several methods have been implemented based on actual" exact="infection" post="control and segregation to control the transmission of COVID-19."/>
 <result pre="various receptors such as IL-6. The major outcome of the" exact="treatment" post="is to reduce the inflammation during the therapy. The"/>
 <result pre="remdesivir has been approved by FDA for the emergency room" exact="treatment" post="of COVID-19, suggesting its promising potency. In addition to"/>
 <result pre="on sharing all influenza data GGO ground-glass opacities RT-PCR real-time" exact="polymerase chain reaction" post="CCR2 CC chemokine receptor 2 CCL2 CC chemokine ligand"/>
 <result pre="patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 39.LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends202014697110.5582/bst.2020.0102031996494 40.NishiuraH.JungS.-M.LintonN.M.KinoshitaR.YangY.HayashiK.KobayashiT.YuanB.AkhmetzhanovA.R.The extent"/>
 <result pre="analysisIntensive Care Med.2020461114111610.1007/s00134-020-06026-132236644 68.ZhangW.ZhaoY.ZhangF.WangQ.LiT.LiuZ.WangJ.QinY.ZhangX.YanX.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): The"/>
 <result pre="Situation Report, 512020Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10(accessed on 11 March 2020) 79.PeelingR.W.WedderburnC.J.GarciaP.J.BoerasD.FongwenN.NkengasongJ.SallA.TanuriA.HeymannD.L.Serology" exact="testing" post="in the COVID-19 pandemic responseLancet Infect. Dis.202010.1016/S1473-3099(20)30517-X 80.ZhaoJ.YuanQ.WangH.LiuW.LiaoX.SuY.WangX.YuanJ.LiT.LiJ.Antibody responses"/>
 <result pre="RT-PCR confirmed COVID-19 and normal chest CTRadiology202029510.1148/radiol.202020070232142398 83.ChanJ.F.-W.YipC.C.-Y.ToK.K.-W.TangT.H.-C.WongS.C.-Y.LeungK.-H.FungA.Y.-F.NgA.C.-K.ZouZ.TsoiH.-W.et al.Improved molecular" exact="diagnosis" post="of COVID-19 by the novel, highly sensitive and specific"/>
 <result pre="vitro and with clinical specimensJ. Clin. Microbiol.20205810.1128/JCM.00310-20 84.MardaniR.VasmehjaniA.A.ZaliF.GholamiA.NasabS.D.M.KaghazianH.KavianiM.AhmadiN.Laboratory parameters in" exact="detection" post="of COVID-19 patients with positive RT-PCR; a diagnostic accuracy"/>
 <result pre="role for monocytes and macrophagesNat. Rev. Immunol.20201810.1038/s41577-020-0331-431792373 94.YeQ.WangB.MaoJ.The pathogenesis and" exact="treatment" post="of the Cytokine Stormâ€™in COVID-19J. Infect.20208060761310.1016/j.jinf.2020.03.03732283152 95.YeQ.WangB.MaoJ.Cytokine storm in"/>
 <result pre="and treatmentJ. Infect.202010.1016/j.jinf.2020.03.037 96.SerbinaN.V.PamerE.G.Monocyte emigration from bone marrow during bacterial" exact="infection" post="requires signals mediated by chemokine receptor CCR2Nat. Immunol.2006731131710.1038/ni130916462739 97.StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.RichardsonP.COVID-19:"/>
 <result pre="FedratinibJ. Microbiol. Immunol. Infect.20205336837010.1016/j.jmii.2020.03.00532205092 100.De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl."/>
 <result pre="https://www.covid19treatmentguidelines.nih.gov/dexamethasone/(accessed on 30 July 2020) 116.GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
 <result pre="futureIndian J. Ophthalmol.20206869332317431 123.HoffmannM.SchroederS.Kleine-WeberH.MÃ¼llerM.A.DrostenC.PÃ¶hlmannS.Nafamostat mesylate blocks activation of SARS-CoV-2: New" exact="treatment" post="option for COVID-19Antimicrob. Agents Chemother.20206410.1128/AAC.00754-2032312781 124.MolinaJ.M.DelaugerreC.GoffJ.Mela-LimaB.PonscarmeD.GoldwirtL.De CastroN.No evidence of"/>
 <result pre="time of publication. ijerph-17-05904-t004_Table 4Table 4 Antivirals included in the" exact="treatment" post="guidelines issued by NHC of China for COVID-19, version"/>
</results>
